MKI67 and mantle cell lymphoma: In exploratory, post-hoc, subgroup analyses we confirm efficacy of rituximab in both, ASCT eligible and ineligible patients as well as across all major MCL subsets, with a trend towards greater benefit for high risk cohorts such as MIPI high risk and Ki67 proliferation index ≥ 30% (Fig. 3a).